Formulation and In Vitro-Ex vivo Evaluation of Cannabidiol and Cannabidiol-Valine-Hemisuccinate Loaded Lipid-Based Nanoformulations for Ocular Applications

Adel Ali Youssef, Ahmed; Hayder Abdelrahman, Muna; Geweda, Mona M.; Varner, Corinne; Joshi, Poorva H; Ghonge, Mihir; Dudhipala, Narendar; Sulochana, Suresh P; Gadepalli, Rama S; Majumdar, Soumyajit

doi:10.1016/j.ijpharm.2024.124110

Cited by 1 publication

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many other non-CB1 and CB2 mechanisms have been proposed to explain the therapeutic effects of CBD, including its agonistic effect on serotonin 5-HT1A receptors and upregulation of anandamide signaling for psychiatric conditions. Further, the agonistic effect on vanilloid transient receptor potential vanilloid subtype 1 (TRPV1), μ and δ receptors for pain regulation, and inhibition of tumor necrosis factor-alpha (TNF-α) in inflammatory [ 15 , 16 , 17 , 18 , 19 ]. Due to these mechanisms of action, CBD can be used as an anti-aging, anti-inflammatory, antioxidant, and for pain relief for topical applications, for multiple sclerosis and neuropathic pain, and as an anticonvulsant for transdermal applications [ 15 , 16 , 17 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Evidence of Cannabidiol Effectiveness Associated or Not with Tetrahydrocannabinol in Topical Administration: A Scope Review

Fava,

Souza,

Santos

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Cannabis sativa is a plant of the Cannabaceae family, whose molecular composition is known for its vast pharmacological properties. Cannabinoids are the molecules responsible for Cannabis sativa potential effects, especially tetrahydrocannabinol and cannabidiol. Scientific development has shown interest in the potential of cannabidiol in various health conditions, as it has demonstrated lower adverse events and great pharmacological potential, especially when administered topically. The present study aims to carry out a scoping review, focusing on the use of cannabidiol, in vivo models, for topical administration. Thus, the methodological approach used by the Joanna Briggs Institute was applied, and the studies were selected based on previously established inclusion criteria. Even though more information regarding the dose to achieve pharmacological potential is still needed, cannabidiol demonstrated potential in treating and preventing different conditions, such as glaucoma, atopic dermatitis, epidermolysis bullosa, and pyoderma gangrenosum.

show abstract